BiotechTube

DE-117B Eye Drops + Latanoprost

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Open Angle Glaucoma

Conditions

Open Angle Glaucoma, Ocular Hypertension

Trial Timeline

Nov 28, 2024 → Mar 31, 2026

NCT ID
NCT06666855

About DE-117B Eye Drops + Latanoprost

DE-117B Eye Drops + Latanoprost is a phase 3 stage product being developed by Santen Pharmaceutical for Open Angle Glaucoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06666855. Target conditions include Open Angle Glaucoma, Ocular Hypertension.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06666855Phase 3Recruiting

Competing Products

20 competing products in Open Angle Glaucoma

See all competitors
ProductCompanyStageHype Score
Ilofotase alfa + PlaceboAM-PharmaPhase 2
44
Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Mankind PharmaPhase 3
77
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
77
Pirtobrutinib + PlaceboEli LillyPhase 1/2
41
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
44
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
44
MicafunginAstellas PharmaApproved
85
SDP-133 + LumiganSun PharmaceuticalPhase 3
77
Brinzolamide ophthalmic suspension + Azopt®Sun PharmaceuticalPhase 3
77
Placebo + LusutrombopagShionogiPhase 2
52
LusutrombopagShionogiPhase 2
52
Avatrombopag + Avatrombopag + PlaceboEisaiPhase 2
52
E5501EisaiPhase 1
33
avatrombopagEisaiPhase 1
33
E5501 + Drug: E5501EisaiPhase 1
33
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
33
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
77
Placebo + Avatrombopag tabletsEisaiPhase 2
52
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
77
avatrombopag + PlaceboEisaiPhase 2
52

Other Products from Santen Pharmaceutical

Eybelis ophthalmic solution 0.002%Approved
85
Aflibercept Injection [Eylea]Approved
85
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Phase 3
77
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionPhase 3
77
DE-111 ophthalmic solution + Tafluprost ophthalmic solution 0.0015% + Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%Phase 3
77